Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma

Hayrullah Derici, Ismail Yaman, Tugrul Tansu, Okay Nazli, Ali Dogan Bozdag, Ali Serdar Isguder

Abstract

Background: The purpose of this study is to evaluate perioperative morbidity, mortality, and the prognostic factors that influence survival of the patients with transmural advanced gastric carcinoma after curative surgical therapy.

Methods: Fifty patients with transmural advanced gastric adenocarcinoma underwent curative resection in our clinic. The records of the patients were reviewed and the prognostic factors such as age, gender, location and size of the tumor, type of surgery, blood transfusion, depth of tumor invasion, lymph node metastases, stage of the disease, grading, vascular invasion, lymph vessel invasion, characteristics of the tumor according to Lauren’s classification, and lymph node ratio were evaluated by using statistical methods.

Results: In a total of 12 patients (24%) major morbidities developed, and five patients (10%) died. The overall survival rate was 48% at 1 year, 31% at 3 years, and 19% at 5 years. Lymph node metastases (P = 0.03), lymph vessel invasion (P = 0.001), blood transfusion (P = 0.021), and lymph node ratio (P = 0.006) were the prognostic features identified by univariate analysis. Among the multiple significant prognostic factors in the univariate analysis only one factor, lymph node ratio, proved to be independently significant in the multivariate analysis (RR: 4.47).

Conclusions: Our data showed that we can expect a good survival for patients with a lymph node ratio less than 0.2.

Keywords: Gastric Cancer; Transmural; Advanced; Morbidity; Mortality; Survival

Introduction

Despite developments in diagnostic and therapeutic modalities, gastric cancer is still the second most common cause of cancer-related death throughout the world [1, 2]. The highest incidences of gastric cancer are reported from Eastern Asia, Eastern Europe, and South America [3]. The prognosis for gastric cancer patients remains poor, especially in advanced stages of the disease. There were about 158,000 deaths from stomach cancer in Europe in 2000 [4]. According to 1999 figures of State’s Statistics Institute, death from gastric cancer was 3.22/100,000 in Turkey [5]. A very rigorous screening program that detects patients in an early stage of the disease was developed in Japan. Up to 70% of all gastric cancers are diagnosed as early cancers in the East, but the rate of gastric cancers identified as early cancers accounts for only about 15% in the West [6].

Patients with transmural advanced gastric cancer (T2N0-T3N2) make up the largest group with uncertain outcome. Although the therapeutic results in this group are variable, the identifying prognostic factors are important to establish a therapeutic strategy [7]. This retrospective study was designed with the aim to evaluate perioperative morbidity, mortality, and the prognostic factors that influence survival of the patients with transmural advanced gastric carcinoma after curative surgical therapy.

Materials and Methods

One hundred and forty-five patients with primary gastric cancer underwent gastric resection in our clinic, between January 1997 and March 2004. Fifty patients (34.5%) with transmural advanced gastric cancer were selected for this retrospective study. Hospital records of the patients were reviewed for clinicopathological findings, morbidity, mortality, and survival. The patients with synchronous distant metastases, peritoneal carcinomatosis, gastric stump carcinoma, recurrent gastric cancer, and those that received noncurative resections (R1, R2) were excluded.

Preoperative work-up included upper gastrointestinal
endoscopy with biopsy, abdominal ultrasound scan, and computed tomography. Diagnostic laparoscopy was selectively performed. Gastrectomy with an intent of D2 lymphadenectomy was performed as described by Nakajima and Kajitani [8]. Total gastrectomy was performed for tumors located on the proximal or middle portions of the stomach and subtotal gastrectomy for distal tumors with curative aim. Staging of the gastric cancer was made with reference to the TNM classification of malignant tumors by the International Union Against Cancer (UICC). The pN category which was established to evaluate different groups of lymph node metastases was used (pN0:0, pN1: 1-6, pN2: 7-15 and pN3: >15) [9]. The extent of lymph node dissection and lymph node ratio (the proportion of the number of positive nodes to the number of all resected nodes) are noted. The patients were put into two groups considering lymph node ratio as less than 0.2, and greater than or equal to 0.2.

The patients were followed up at regular intervals by outpatient visits and telephone interviews. The cases that died in the early postoperative period were excluded from the survival analysis. Survival curves were estimated using the Kaplan-Meier method and differences in survival were compared by the log-rank test. Survival was calculated from the date of operation to the date of death, or to the date of last follow-up for the surviving patients. Median survival time was given with their standard error (SE). Simultaneous associations of multiple variables were performed using the Cox proportional hazards regression model to estimate the simultaneous effect on overall survival. Association of the independent prognostic factors, which were age, gender, location and size of the tumor, type of surgery, blood transfusion, depth of tumor invasion (pT), lymph node metastases (pN), stage of the disease, grading, vascular invasion, lymph vessel invasion, characteristics of the tumor according to Lauren’s classification, and lymph node ratio with patients’ survival were evaluated by using univariate analysis methods. Independent variables that showed statistical significance in the univariate analysis were then entered in the multivariate analysis. The prognostic factors were compared by hazard ratio and the 95% confidence interval (CI). Stepwise selection was used to find the most significant factors. A P value of less than 0.05 was considered statistically significant for all patients. Statistical Package for Social Sciences (SPSS 10.0, Chicago, IL, USA) for Windows (Microsoft) was used for the statistical analyses.

Results

Of the 50 patients, 30 (60%) were male and 20 (40%) were female, with a median age of 61 years (range 31 - 77 years). Total gastrectomy was performed in 25 patients and subtotal gastrectomy in the other 25. Histopathological examination of the resected tumors revealed that all of the cases were adenocarcinoma: 38% of them were intestinal type and 62% were diffuse type. The most common site of the primary lesion was antrum (25 cases, 50%). The majority of the tumors were pT3 (39 cases, 78%). All patients had received D2 lymphadenectomy. The median count of dissected lymph nodes was 34 ranging between 25 and 46. Distribution of the cases according to lymph node metastases was as follows: pN0:10 cases, pN1:28 cases, and pN2:12 cases.

Deaths during the first postoperative month were considered surgical mortality. A total of 16 major morbidities developed in 12 patients (24%). Anastomotic leakage was observed in five cases, duodenal stump dehiscence in three cases, abdominal abscess, pneumonia, and ileus in two cases for each, hemorrhage, and myocardial infarction in one case for each. Five patients (10%) died due to these complications and they were excluded from the survival analysis.

Thirty-six patients received postoperative concomitant radio-chemotherapy as adjuvant treatment. All of them

![Figure 1](image1.png) Overall survival curve of the patients with transmural gastric carcinoma calculated by the method of Kaplan-Meier.

![Figure 2](image2.png) Survival according to nodal involvement. The survival rate for the patients with pN2 lymph node metastases was lower than the rate for pN1 and pN0 cases. (P = 0.0400, log-rank test.)
Table 1. Univariate Analysis of The Prognostic Factors In Patients With Transmural Gastric Cancer

| Parameters                        | No. of patients | Median survival (month ± SE) | 95% Confidence Interval | \( p^* \) | Survival rate (%) 1-year | Survival rate (%) 3-years | Survival rate (%) 5-years | \( p^\dagger \) |
|-----------------------------------|-----------------|------------------------------|-------------------------|----------|--------------------------|---------------------------|--------------------------|----------|
| Age (years)                       |                 |                              |                         |          |                          |                           |                           |          |
| ≤65                               | 30              | 25.0 ± 7.25                  | 27.88 – 48.77           | NS       | 52                       | 40                         | 20                        |          |
| >65                               | 15              | 16.0 ± 9.02                  | 0 – 33.67               | NS       | 39                       | 13                         | 13                        |          |
| Gender                            |                 |                              |                         |          |                          |                           |                           |          |
| Male                              | 27              | 21.0 ± 3.44                  | 14.25 – 27.75           | NS       | 44                       | 25                         | 25                        |          |
| Female                            | 18              | 27.0 ± 7.80                  | 11.70 – 42.30           | NS       | 53                       | 41                         | 0                         |          |
| Tumor location                    |                 |                              |                         |          |                          |                           |                           |          |
| Cardia                            | 9               | 30.0 ± 7.28                  | 15.73 – 44.27           | NS       | 49                       | 32                         | 0                         |          |
| Corpus                            | 11              | 18.0 ± 3.48                  | 11.17 – 24.83           | NS       | 35                       | 35                         | 35                        |          |
| Antrum                            | 22              | 24.0 ± 3.03                  | 18.07 – 29.93           | NS       | 55                       | 35                         | 35                        |          |
| Diffuse                           | 3               | 0                            | 0                       | NS       | 20                       | 28                         | 28                        |          |
| Tumor size (cm)                   |                 |                              |                         |          |                          |                           |                           |          |
| >10 in diameter                   | 24              | 24.0 ± 5.30                  | 13.61 – 34.39           | NS       | 54                       | 36                         | 18                        |          |
| ≤10 in diameter                   | 21              | 21.0 ± 2.28                  | 16.53 – 25.47           | NS       | 43                       | 28                         | 28                        |          |
| Depth of tumor invasion           |                 |                              |                         |          |                          |                           |                           |          |
| pT2                               | 11              | 62.0 ± 19.12                 | 24.52 – 99.48           | NS       | 53                       | 53                         | 26                        |          |
| pT3                               | 34              | 18.0 ± 5.38                  | 7.45 – 28.55            | NS       | 46                       | 26                         | 18                        |          |
| Lymph node metastases             |                 |                              |                         | 0.0400   |                          |                            |                           | 0.030    |
| pN0                               | 10              | -                            | -                       | 78       | 65                       | 65                         |                           |          |
| pN1                               | 25              | 21.0 ± 2.38                  | 16.33 – 25.67           | 37       | 27                       | 13                         |                           |          |
| pN2                               | 10              | 16.0 ± 6.39                  | 3.47 – 28.53            | 46       | 11                       | 11                         |                           |          |
| Stage                             |                 |                              |                         |          |                          |                           |                           |          |
| I B                               | 3               | -                            | -                       | 100      | 100                      | 100                        |                           |          |
| II                                | 16              | 21.0 ± 5.04                  | 11.13 – 30.87           | 46       | 37                       | 0                          |                           |          |
| III A                             | 17              | 18.0 ± 4.84                  | 8.52 – 27.48            | 38       | 25                       | 25                         |                           |          |
| III B                             | 9               | 24.0 ± 6.01                  | 12.21 – 35.79           | 51       | 13                       | -                          |                           |          |
| Grading                           |                 |                              |                         | 0.0170   |                          |                            |                           | NS       |
| G1                                | 6               | -                            | -                       | 100      | 100                      | 100                        |                           |          |
| G2                                | 6               | 21.0 ± 9.19                  | 3.0 – 39.0              | 50       | 33                       | 0                          |                           |          |
| G3                                | 33              | 18.0 ± 3.39                  | 11.36 – 24.64           | 38       | 19                       | 19                         |                           |          |
| Type of Surgery                   |                 |                              |                         |          |                          |                           |                           |          |
| Subtotal gastrectomy              | 22              | 24.0 ± 3.03                  | 18.07 – 29.93           | 55       | 35                       | 35                         |                           |          |
| Total gastrectomy                 | 23              | 20.0 ± 3.16                  | 13.81 – 26.19           | 41       | 28                       | 0                          |                           |          |
| Vascular invasion                 |                 |                              |                         |          |                          |                           |                           |          |
| Absent                            | 26              | 25.0 ± 5.07                  | 15.07 – 34.93           | 54       | 35                       | 35                         |                           |          |
| Present                           | 19              | 21.0 ± 2.05                  | 16.99 – 25.01           | 39       | 26                       | 9                          |                           |          |
| Lymph vessel invasion             |                 |                              |                         | 0.0003   |                          |                            |                           | 0.001    |
| Absent                            | 17              | 62.0 ± 22.96                 | 17.0 – 107.0            | 80       | 64                       | 22                         |                           |          |
| Present                           | 28              | 15.0 ± 2.55                  | 10.01 – 19.99           | 29       | 12                       | 12                         |                           |          |
| Blood transusions                 |                 |                              |                         | 0.0166   |                          |                            |                           | 0.021    |
| < 500 ml                          | 27              | 27.0 ± 6.85                  | 13.58 – 40.42           | 57       | 44                       | 44                         |                           |          |
| ≥ 500 ml                          | 18              | 16.0 ± 5.63                  | 4.97 – 27.03            | 32       | 13                       | 4                          |                           |          |
| Lauren’s classification           |                 |                              |                         | NS       |                          |                            |                           | NS       |
| Intestinal                        | 16              | 25.0 ± 6.0                   | 13.24 – 36.76           | 63       | 42                       | 42                         |                           |          |
| Diffuse                           | 29              | 18.0 ± 3.62                  | 10.90 – 25.10           | 39       | 25                       | 8                          |                           |          |
| Lymph node ratio                  |                 |                              |                         | 0.0012   |                          |                            |                           | 0.006    |
| < 0.2                             | 12              | 24.0 ± 2.45                  | 19.19 – 28.81           | 52       | 34                       | 20                         |                           |          |
| ≥ 0.2                             | 33              | 5.0 ± 2.0                    | 1.08 – 8.92             | -        | -                        | -                          |                           |          |
| All patients                      | 45              | 23.0 ± 2.51                  | 18.07 – 27.93           | 48       | 31                       | 19                         |                           |          |

SE: Standard error, \( p^* \): Log-rank test, \( p^\dagger \): Chi-square test, NS: Not significant
completed the whole course of adjuvant treatment. Nine patients did not receive adjuvant therapy due to postoperative complications (four patients), or patient’s refusal to receive radio-chemotherapy (five patients).

Mean hospital stay was 13.5 days (8 - 40 days). Median follow-up was 25 months (range 2 - 74 months). During follow-up period 29 patients died of gastric cancer and 16 patients are still alive. The overall survival rate was 48% at 1 year, 31% at 3 years, and 19% at 5 years, and median survival time was 23.00 ± 2.51 months, 95% CI (18.07 - 27.93). There was no significant difference in survival between the patients with pT2 and pT3 tumors, nor between stage III B disease and the other stages. Median survival time was 24.0 ± 2.45 months, 95% CI (19.19 - 28.81), for the patients with a lymph node ratio less than 0.2; and 5.0 ± 2.0 months, 95% CI (1.08 - 8.92), for those with a lymph node ratio greater or equal to 0.2 (P = 0.0012, log-rank test).

Univariate analysis was performed to evaluate the relationship between clinicopathological features and patients’ survival. Of the 14 clinical and pathological variables entered in the analysis, four were found to have significant influence. Lymph node metastases (P = 0.030), lymph vessel invasion (P = 0.001), blood transfusion (P = 0.021), and lymph node ratio (P = 0.006) were the prognostic features identified by univariate analysis. Evaluation of the prognostic factors for the cases and the results of univariate analysis are shown in Table 1. Among multiple significant prognostic factors in the univariate analysis, only one factor, lymph node ratio, proved to be independently significant in the multivariate analysis, risk ratio 4.47, 95% CI (1.168 - 17.117) (Table 2).

The overall survival curve and the survival curves according to lymph node metastases, lymph vessel invasion, equal to 0.2 (P = 0.0012, log-rank test).

Table 2. Multivariate Analysis of the Independent Prognostic Factors

| Parameters                        | RR   | 95% CI           | P    |
|-----------------------------------|------|------------------|------|
| Lymph node metastases            |      |                  |      |
| (pN1 vs pN0)                      | 1.11 | 0.285 – 4.341    | 0.877|
| (pN2 vs pN0)                      | 1.46 | 0.282 – 7.544    | 0.652|
| Lymph vessel invasion            |      |                  |      |
| (Extensive vs not extensive)      | 1.39 | 0.444 – 4.379    | 0.559|
| Blood transfusions                |      |                  |      |
| (≥ 500 ml vs < 500 ml)            | 1.01 | 0.433 – 2.362    | 0.979|
| Lymph node ratio                  |      |                  |      |
| (≥ 0.2 vs < 0.2)                  | 4.47 | 1.168 – 17.117   | 0.029|

P: Cox’s proportional hazards model. CI: Confidence Interval. RR: Relative Risk

Figure 3. Survival according to lymph vessel invasion. The survival rate for patients with lymph vessel invasion was lower than the rate for the patients without lymph vessel invasion. (P = 0.0003, log-rank test).

Figure 4. Survival according to blood transfusion. Survival rate for the patients that received blood transfusions more than or equal to 500 ml was lower than the rate for the patients that received less than 500 ml. (P = 0.0166, log-rank test).
motherapy with 5-flourouracil/leucovorin and 5-fluorouracil/leucovorin + 45 Gy radiotherapy, showed that adjuvant radio-chemotherapy significantly improves survival [17]. Thus, adjuvant radio-chemotherapy for surgically treated gastric cancer patients is advocated by the oncology group in our hospital as in many other centers [6].

The prognosis for patients with transmural advanced gastric carcinoma has been improved by curative surgery [7]. Several reports have demonstrated that the significant prognostic factors are the stage of the disease, lymph node status, and the depth of penetration into the gastric wall [12, 14, 18]. Five-year survival rate after curative surgical resection ranges from 50% to 70% in patients with stage II disease and from 29% to 42% in patients with stage III disease [10, 12]. In our series, the patients with pT2 and stage IB disease had better survival than those with pT3 and the other stages, but they were not significant variables in univariate analysis. In Dhar’s [7] series 49% of the patients survived more than 7 years whereas 5-year survival rate was 19% in this study. Five-year survival rates indicate the difference between patients in the West and in the East, and that the prognosis of resectable gastric carcinoma in the West remains poor. The survival rate that we obtained in this study is comparable with those from the Western countries but lower than those from Japan. Better results of the Japanese series may be due to early diagnosis, different tumor biology, patient type, and extended lymphadenectomy.

It has been reported that the prognosis of the patients with gastric cancer is influenced most strongly by lymph node involvement. Moreover, lymphatic spread is reported to be one of the most relevant prognostic factors in advanced gastric cancer resected for cure [18, 19]. Since risk of relapse and overall survival are also highly dependent on the number of lymph node metastases, overall survival of the patients with no lymph node metastasis is about 40-80% [20]. In the present study, 5-year survival rate in relation to lymph node involvement was 65%, 13%, and 11% for pN0, pN1, and pN2, respectively and it was one of the significant prognostic factors by univariate analysis (P = 0.030).

Studies that have been published during last few years emphasize the prognostic importance of lymph vessel invasion. Yokota et al found that lymphatic vessel invasion is an unfavorable prognostic factor for gastric cancer [18]. Also, von Rahden et al reported lymphatic vessel invasion as a prognostic factor in patients with resected primary adenocarcinomas of the esophagogastric junction [21]. In our study, lymphatic vessel invasion was found to be one of the prognostic factors by the univariate analysis (P = 0.001).

Multiple blood transfusions have been reported to be associated with poor survival rate, and have been determined as an independent risk factor for poor prognosis by multivariate analysis in several studies [22, 23]. In a retrospective study on 1000 patients that had undergone curative surgery for gastric cancer at the National Cancer Center Hospital in

**Figure 5.** Survival according to lymph node ratio. Survival rate for patients with a lymph node ratio greater than or equal to 0.2 was lower then the rate for those with a lymph node ratio less than 0.2. (P = 0.0012, log-rank test).
Japan from 1976 to 1981, statistical analysis revealed significant adverse influence of blood transfusions on survival [24]. In our study, blood transfusions more than 500 ml was one of the significant prognostic factors by univariate analysis (P = 0.021).

Lymph node ratio may give more accurate prognostic information about nodal involvement than the current pN category. Several authors have already suggested the role of lymph node ratio as a prognostic factor [14, 25, 26]. Siewert et al reported relevant prognostic factors in 1182 patients with gastric cancer undergoing R0 resection and they noted that lymph node ratio and lymph node status were the most important prognostic factors in patients with resected gastric cancer [26]. Analyzing the survival by comparing lymph node ratio against the number of involved lymph nodes, Santiago et al have demonstrated that the ratio stands out as the best prognostic factor [25]. The results of our study show that lymph node ratio was the only important predictor in patients with transmural gastric cancer (P = 0.029, RR:4.47).

In conclusion, lymph node metastases, lymph vessel invasion, blood transfusions (more than or equal to 500 ml), and lymph node ratio (greater than or equal to 0.2) were found as significant prognostic factors by the univariate analysis in this study. However, lymph node ratio was the strongest predictor of survival in multivariate analysis. Our data showed that we can expect a good survival for patients with a lymph node ratio less than 0.2, when extended lymph node dissection is performed.

**Competing Interest**

The authors of this article claim to have no financial interest in any company or any of the products mentioned in this article.

**References**

1. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Data Base report on gastric carcinoma. Cancer 1997;80(12):2333-2341.
2. Wu CW, Hsieh MC, Lo SS, Lui WY, P'Eng F K. Quality of life of patients with gastric adenocarcinoma after curative gastrectomy. World J Surg 1997;21(7):777-782.
3. Pisters PWT, Kelsen DP, Powell SM, Tepper JE. Cancer of the stomach. In Devita VT Jr., Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams&Wilkins, 2005:909-944.
4. Catalano V, Labianca R, Beretta GD, Gatta G, de Braud F, Van Cutsem E. Gastric cancer. Crit Rev Oncol Hematol 2005;54(3):209-241.
5. Sokmen HM. Epidemiology. In Mihmanli M, ed. Gastric Cancer and Surgical Treatment. 1st ed. Istanbul: Avrupa Tip Kitapcilik, 2004:15-19.
6. Siewert JR. Gastric cancer: the dispute between East and West. Gastric Cancer 2005;8(2):59-61.
7. Dhar DK, Kubota H, Tachibana M, Kotoh T, Tabara H, Watanabe R, Kohno H, et al. Long-term survival of transmural advanced gastric carcinoma following curative resection: multivariate analysis of prognostic factors. World J Surg 2000;24(5):588-593; discussion 593-594.
8. Nakajima T, Kajitani T. Surgical treatment of gastric cancer with special reference to lymphnode dissection. Excerpta Med 1981;53:207-225.
9. Sobin LH, Wittekind Ch, eds. UICC: TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss, 2002.
10. Yildirim E, Celen O, Berberoglu U. The Turkish experience with curative gastrectomies for gastric carcinoma: is D2 dissection worthwhile? J Am Coll Surg 2001;192(1):25-37.
11. Sasaki M, Katai H, Sano T, Maruyama K. Management of complications after gastrectomy with extended lymphadenectomy. Surg Oncol 2000;9(1):31-34.
12. Zhang XF, Huang CM, Lu HS, Wu XY, Wang C, Guang GX, Zhang JZ, et al. Surgical treatment and prognosis of gastric cancer in 2,613 patients. World J Gastroenterol 2004;10(23):3405-3408.
13. Ikekuchi M, Oka S, Gomyo Y, Tsujitani S, Maeta M, Kaibara N. Postoperative morbidity and mortality after gastrectomy for gastric carcinoma. Hepatogastroenterology 2001;48(41):1517-1520.
14. Gockel I, Pietzka S, Gonner U, Hommel G, Junginger T. Subtotal or total gastrectomy for gastric cancer: impact of the surgical procedure on morbidity and prognosis-analysis of a 10-year experience. Langenbecks Arch Surg 2005;390(2):148-155.
15. Bottcher K, Siewert JR, Roder JD, Busch R, Hermanek P, Meyer HJ. [Risk of surgical therapy of stomach cancer in Germany. Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group (‘92)]. Chirurg 1994;65(4):298-306.
16. Buroker T, Kim PN, Groppe C, McCracken J, O’Bryan R, Panettiere F, Costanzi J, et al. 5FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer: a Southwest Oncology Group Study. Cancer 1979;44(4):1215-1221.
17. Macdonald JS, Smallrey SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345(10):725-730.
18. Yokota T, Ishiyama S, Saito T, Teshima S, Narushima Y, Murata K, Iwamoto K, et al. Lymph node metastasis as...
a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol 2004;39(4):380-384.
19. Isozaki H, Okajima K, Ichinona T, Fujii K, Nomura E, Izumi N, Ohyama T. Distant lymph node metastasis of early gastric cancer. Surg Today 1997;27(7):600-605.
20. Takagane A, Terashima M, Abe K, Araya M, Irinoda T, Yonezawa H, Nakaya T, et al. Evaluation of the ratio of lymph node metastasis as a prognostic factor in patients with gastric cancer. Gastric Cancer 1999;2(2):122-128.
21. von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol 2005;23(4):874-879.
22. Hyung WJ, Noh SH, Shin DW, Huh J, Huh BJ, Choi SH, Min JS. Adverse effects of perioperative transfusion on patients with stage III and IV gastric cancer. Ann Surg Oncol 2002;9(1):5-12.
23. Bortul M, Calligaris L, Roseano M, Leggeri A. Blood transfusions and results after curative resection for gastric cancer. Suppl Tumori 2003;2(5):S27-30.
24. Kampschoer GH, Maruyama K, Sasako M, Kinoshita T, van de Velde CJ. The effects of blood transfusion on the prognosis of patients with gastric cancer. World J Surg 1989;13(5):637-643.
25. Rodriguez Santiago JM, Munoz E, Marti M, Quintana S, Veloso E, Marco C. Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg Oncol 2005;31(1):59-66.
26. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 1998;228(4):449-461.